TelyRx Taps U.S. Market with OTCQX Listing to Fuel Digital Pharmacy Growth

NEW YORK, NY – June 05, 2026 – In a significant strategic shift, Canadian-based TelyRx Holdings Inc. has officially begun trading on the OTCQX Best Market, the top tier of OTC Markets Group. The move, under the ticker symbol “TELYF,” provides the technology-enabled pharmacy services company with direct access to the world’s largest capital market, signaling a new phase in its ambitious U.S. expansion plans.

This cross-listing is more than a procedural update; it represents a calculated maneuver to enhance liquidity, broaden its investor base, and fuel its growth within the hyper-competitive U.S. digital healthcare landscape. While continuing to trade on the Toronto Stock Exchange (TSX: TELY), the company now offers U.S. investors a streamlined way to participate in its growth story, trading its shares in U.S. dollars during U.S. market hours.

A Strategic Play for U.S. Capital and Visibility

For international growth companies, listing on a U.S. market is a well-established pathway to unlocking significant value, and TelyRx’s qualification for OTCQX is a textbook example. The primary benefit is gaining efficient, cost-effective access to the deep pool of U.S. retail and institutional investors. This expanded access is critical for a company in a high-growth phase, as it provides a new channel for raising capital to fund operations, marketing, and technological development.

Market analysts note that increased visibility in the U.S. can create a virtuous cycle. As more investors become aware of the company, trading volume can increase, which in turn can lead to a more stable and potentially higher valuation. Studies on OTCQX-listed international companies have shown an average increase in home-market daily trading volume, suggesting the move can enhance liquidity on both sides of the border.

Furthermore, the OTCQX market structure offers a distinct advantage for firms like TelyRx. By utilizing the SEC’s Rule 12g3-2(b) exemption, the company can leverage its existing TSX reporting and disclosure obligations to keep U.S. investors informed. This avoids the often costly and duplicative requirements of a full U.S. exchange registration, such as those for NASDAQ or the NYSE, making it a highly efficient strategy for established international issuers.

Riding the Digital Pharmacy Wave

TelyRx’s move comes at a time of explosive growth in the digital health sector. The global online pharmacy market, valued at over $130 billion in 2024, is projected to surge to nearly $475 billion by 2032, driven by consumer demand for convenience, transparency, and contactless services. The U.S. market alone is forecast to grow at a compound annual rate of nearly 17%.

Within this burgeoning landscape, TelyRx has carved out a specific and compelling niche. The company operates a vertically integrated platform that connects patients with licensed providers for over 450 common medications. It then fulfills prescriptions through its own licensed pharmacies in Florida and Texas, delivering directly to customers in 48 states. Its key differentiator is a “cash-pay” model that bypasses complex insurance networks, offering transparent, upfront pricing. This appeals to a growing segment of consumers, particularly those who are uninsured, underinsured, or simply seeking privacy and simplicity.

The strategy is showing powerful results. For the first quarter ended March 31, 2026, TelyRx reported revenues of $19.4 million, a staggering 180% increase from the same period in 2025. This top-line growth, built on a substantial increase in prescriptions filled, demonstrates strong market validation for its model. While the company posted a net loss of $4.7 million in the same quarter, this is largely attributed to aggressive investments in marketing and operations—expenses typical for a company aggressively scaling to capture market share.

The OTCQX Stamp of Approval

Qualifying for the OTCQX Best Market is not a trivial accomplishment. It serves as a seal of approval that distinguishes a company from the speculative nature often associated with over-the-counter securities. To be eligible, companies must meet high financial standards, adhere to best practices in corporate governance, and demonstrate full compliance with applicable securities laws. Penny stocks and shell companies are explicitly barred.

This rigorous vetting process provides a layer of assurance for investors. OTCQX companies are required to remain current in their financial disclosures and undergo annual financial audits by a PCAOB-registered firm. For U.S. investors, this means access to the same caliber of real-time quotes and financial data they would expect from a national exchange-listed company, all available through the OTC Markets website. This commitment to transparency is crucial for building the investor trust necessary to support a company's long-term growth.

Unlocking Value for Investors and Patients

By joining OTCQX, TelyRx is effectively lowering the barrier to entry for a vast new pool of American investors. The ability to trade TELYF directly through U.S. brokerage accounts, in U.S. dollars, simplifies the investment process and makes the company’s stock accessible to a wider audience that might be hesitant to trade on foreign exchanges.

The company has already signaled its intent to engage this new audience, with its executive team recently presenting at virtual investor conferences aimed at the U.S. market. The capital and visibility gained from this listing are expected to directly fuel the company's core mission: scaling its disruptive pharmacy model. This includes expanding its formulary, enhancing its technology platform, and reaching more patients who are seeking a frictionless, direct-to-consumer healthcare experience.

For TelyRx, the move to OTCQX is a pivotal step that aligns its capital markets strategy with its operational ambitions, positioning it to better compete against larger players like Amazon Pharmacy and Hims & Hers. As the U.S. healthcare system continues its digital transformation, TelyRx’s enhanced presence in the American financial ecosystem provides it with the resources needed to capture a meaningful share of this rapidly evolving market.